Limits...
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M, Farah ME, Fromow-Guerra J, Morales-Canton V - J Ophthalmol (2011)

Bottom Line: This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup.The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME.Surgery should be performed 4 days after IVB.

View Article: PubMed Central - PubMed

Affiliation: Retina and Vitreous Service, Caracas Clinical Opthalmology Center, Caracas 1010, Venezuela.

ABSTRACT
This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.

No MeSH data available.


Related in: MedlinePlus

Changes in best-corrected visual acuity (BCVA) after intravitreal bevacizumab. BCVA improved at 1 month from 0.90 to 0.76 (logarithm of the minimum angle of resolution), a difference that was statistically significant (P < .001), this level of BCVA was maintained throughout 3-, 6-, 12-, and 24-months. CI: confidence interval (Reprinted with permission from [13]).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3090772&req=5

fig1: Changes in best-corrected visual acuity (BCVA) after intravitreal bevacizumab. BCVA improved at 1 month from 0.90 to 0.76 (logarithm of the minimum angle of resolution), a difference that was statistically significant (P < .001), this level of BCVA was maintained throughout 3-, 6-, 12-, and 24-months. CI: confidence interval (Reprinted with permission from [13]).

Mentions: Within one month after the initial bevacizumab injection, improvements in BCVA and central macular thickness (CMT) measurements were observed and these significant changes continued throughout the 24-month followup. At one month BCVA improved from log MAR = 0.90 to 0.76, a difference that was statistically significant (P < .001) (P = .0001). This improvement in BCVA was maintained throughout the 3-, 6-, 12-, and 24-month followup, (Figure 1). In addition, the mean BCVA at 24 months was 20/100, log MAR = 0.70 (P < .001) a statistically significant difference from baseline BCVA. Twenty-four month BCVA analysis by subgroups demonstrated that 62 (44.6%) eyes remained stable, 72 (51.8%) eyes improved two or more ETDRS lines of BCVA, and 5 (3.6%) eyes decreased two or more ETDRS lines of BCVA.


Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M, Farah ME, Fromow-Guerra J, Morales-Canton V - J Ophthalmol (2011)

Changes in best-corrected visual acuity (BCVA) after intravitreal bevacizumab. BCVA improved at 1 month from 0.90 to 0.76 (logarithm of the minimum angle of resolution), a difference that was statistically significant (P < .001), this level of BCVA was maintained throughout 3-, 6-, 12-, and 24-months. CI: confidence interval (Reprinted with permission from [13]).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3090772&req=5

fig1: Changes in best-corrected visual acuity (BCVA) after intravitreal bevacizumab. BCVA improved at 1 month from 0.90 to 0.76 (logarithm of the minimum angle of resolution), a difference that was statistically significant (P < .001), this level of BCVA was maintained throughout 3-, 6-, 12-, and 24-months. CI: confidence interval (Reprinted with permission from [13]).
Mentions: Within one month after the initial bevacizumab injection, improvements in BCVA and central macular thickness (CMT) measurements were observed and these significant changes continued throughout the 24-month followup. At one month BCVA improved from log MAR = 0.90 to 0.76, a difference that was statistically significant (P < .001) (P = .0001). This improvement in BCVA was maintained throughout the 3-, 6-, 12-, and 24-month followup, (Figure 1). In addition, the mean BCVA at 24 months was 20/100, log MAR = 0.70 (P < .001) a statistically significant difference from baseline BCVA. Twenty-four month BCVA analysis by subgroups demonstrated that 62 (44.6%) eyes remained stable, 72 (51.8%) eyes improved two or more ETDRS lines of BCVA, and 5 (3.6%) eyes decreased two or more ETDRS lines of BCVA.

Bottom Line: This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup.The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME.Surgery should be performed 4 days after IVB.

View Article: PubMed Central - PubMed

Affiliation: Retina and Vitreous Service, Caracas Clinical Opthalmology Center, Caracas 1010, Venezuela.

ABSTRACT
This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.

No MeSH data available.


Related in: MedlinePlus